SSA
ANTX icon

Schonfeld Strategic Advisors’s AN2 Therapeutics ANTX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,281
Closed -$16.3K – 2189
2025
Q4 		$16.3K Hold
14,281
– – ﹤0.01% 1940
2025
Q3 		$18.1K Sell
14,281
-2,834
-17% -$3.24K ﹤0.01% 2109
2025
Q2 		$18.1K Sell
17,115
-3,000
-15% -$3.58K ﹤0.01% 1940
2025
Q1 		$27.4K Sell
20,115
-6,785
-25% -$8.54K ﹤0.01% 2091
2024
Q4 		$37.1K Sell
26,900
-39,200
-59% -$47.5K ﹤0.01% 1886
2024
Q3 		$70.7K Buy
66,100
+44,326
+204% +$76.9K ﹤0.01% 1880
2024
Q2 		$46.8K Buy
+21,774
New +$51.8K ﹤0.01% 1937

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Schonfeld Strategic Advisors's ANTX Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of AN2 Therapeutics (ANTX) in Q1 2026, closing a stake of 14,281 shares — an estimated $16.3K sold.

Schonfeld Strategic Advisors first reported a position in ANTX in Q2 2024 and held it in 7 quarters. The position peaked at $70.7K in Q3 2024. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • Schonfeld Strategic Advisors reported no remaining AN2 Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 14,281 AN2 Therapeutics shares in Q1 2026, an estimated $16.3K.
  • Schonfeld Strategic Advisors first reported a position in AN2 Therapeutics in Q2 2024 and held it in 7 quarters.
  • Schonfeld Strategic Advisors's AN2 Therapeutics position peaked at $70.7K in Q3 2024.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.